A Study of Guselkumab in Participants With Familial Adenomatous Polyposis

PHASE1CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

November 19, 2018

Primary Completion Date

September 13, 2021

Study Completion Date

March 23, 2022

Conditions
Adenomatous Polyposis Coli
Interventions
DRUG

Guselkumab

Guselkumab SC will be administered every 4 weeks.

DRUG

Placebo

Placebo SC will be administered every 4 weeks.

Trial Locations (32)

8035

Hosp Univ Vall D Hebron, Barcelona

8036

Hosp Clinic de Barcelona, Barcelona

10032

Herbert Irving Comprehensive Cancer Center Columbia University Medical Center, New York

13385

APHM Hopital Timone, Marseille

19104

University of Pennsylvania - Perelman School of Medicine, Philadelphia

19111

Fox Chase Cancer Center, Philadelphia

32224

Mayo Clinic Jacksonville, Jacksonville

33136

University of Miami, Miami

33606

University of South Florida, Tampa

43210

Wexner Medical Center at the Ohio State University, Columbus

44195

Cleveland Clinic, Cleveland

53127

Universitatsklinikum Bonn, Bonn

63110

Washington University School Of Medicine, St Louis

64239

Sourasky MC, Tel Aviv

69437

Hopital Edouard Herriot - CHU Lyon, Lyon

70121

Ochsner Medical Center, New Orleans

77030

University of Texas MD Anderson Cancer Center, Houston

84132

University of Utah Huntsman Cancer Institute, Salt Lake City

85054

Mayo Clinic, Phoenix

89070

Universitatsklinikum Ulm, Ulm

91010

City of Hope, Duarte

98195

University of Washington, Seattle

06519

Yale University, New Haven

02114

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

1105 AZ

Academisch Medisch Centrum Universiteit van Amsterdam, Amsterdam

2333 ZA

Leiden University Medical Center, Leiden

3015 GD

Erasmus MC, Rotterdam

60 355

Szpital Kliniczny im Heliodora Swiecickiego Uniwersytetu Medycznego im Karola Marcinkowskiego w Po, Poznan

02-781

Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy, Warsaw

00935

Pan American Center for Oncology Trials LLC, Rio Piedras

171 76

Karolinska Universitetssjukhuset, Stockholm

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03649971 - A Study of Guselkumab in Participants With Familial Adenomatous Polyposis | Biotech Hunter | Biotech Hunter